{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:59:54Z","timestamp":1790675994327,"version":"4.1.0"},"reference-count":18,"publisher":"Tech Science Press","issue":"4","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Cytokine Netw"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1684\/ecn.2019.0436","type":"journal-article","created":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T17:52:56Z","timestamp":1697824376000},"page":"130-134","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["IL-8 as a potential biomarker in Guillain-Barre Syndrome"],"prefix":"10.32604","volume":"30","author":[{"given":"Gautier","family":"Breville","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agustina M.","family":"Lascano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Roux-Lombard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice H.","family":"Lalive","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"17807","published-online":{"date-parts":[[2020,3,2]]},"reference":[{"issue":"3","key":"436_CR1","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/jns.12266","volume":"23","author":"L Alessandro","year":"2018","unstructured":"Alessandro L, Pastor Rueda JM, Wilken M, et al. Differences between acute-onset chronic inflammatory demyelinating polyneuropathy and acute inflammatory demyelinating polyneuropathy in adult patients. J Peripher Nerv Syst 2018; 23(3):154\u20138.","journal-title":"J Peripher Nerv Syst"},{"key":"436_CR2","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1056\/NEJMra1114525","volume":"14","author":"N Yuki","year":"2012","unstructured":"Yuki N, Hartung HP. Guillain-Barre syndrome. N Engl J. Med 2012; 14:2294\u2013304.","journal-title":"N Engl J. Med"},{"key":"436_CR3","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1474-4422(08)70215-1","volume":"7","author":"PA van Doom","year":"2008","unstructured":"van Doom PA, Ruts L, Jacobs BC. Clinical features, pathogenesis and treatment of Guillain-Barre syndrome. Lancet Neurol 2008; 7:939\u201350.","journal-title":"Lancet Neurol"},{"key":"436_CR4","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1212\/WNL.0b013e3181e07d14","volume":"74","author":"L Ruts","year":"2010","unstructured":"Ruts L, Drenthen J, Jacobs BC, Van Doom PA. Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome. A. prospective study. Neurology 2010; 74:1680\u20136.","journal-title":"Neurology"},{"key":"436_CR5","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/0140-6736(93)93070-H","volume":"341","author":"R Hughes","year":"1993","unstructured":"Hughes R. Guillain-Barre Syndrome Steroid Trial Group. Double-blind trial of intravenous methylprednisolone in Guillain-Barre syndrome. Lancet 1993; 341:586\u201390.","journal-title":"Lancet"},{"key":"436_CR6","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/nrneurol.2011.121","volume":"7","author":"MC Dalakas","year":"2011","unstructured":"Dalakas MC. Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat Rev Neurol 2011; 7:507\u201311.","journal-title":"Nat Rev Neurol"},{"key":"436_CR7","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.7150\/thno.15625","volume":"7","author":"H Ha","year":"2017","unstructured":"Ha H, Debnath B, Neamati N. Role of the CXCL8-CXCR1\/2 axis in cancer and inflammatory diseases. Theranostics 2017; 7:1543\u201388.","journal-title":"Theranostics"},{"issue":"Suppl1","key":"436_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1046\/j.1365-2222.2000.00092.x","volume":"30","author":"AP Sampson","year":"2000","unstructured":"Sampson AP. The role of eosinophils and neutrophils in inflammation. Clinical and experimental allergy. Clin Exp Allergy 2000; 30(Suppl 1):22\u20137.","journal-title":"Clin Exp Allergy"},{"key":"436_CR9","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1023\/A:1024532715775","volume":"23","author":"R Press","year":"2003","unstructured":"Press R, Pashenkov M, Jin JP, Link H. Aberrated levels of cerebrospinal fluid chemokines in Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. J Clin Immunol 2003; 23:259\u201367.","journal-title":"J Clin Immunol"},{"key":"436_CR10","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/B978-0-12-804279-3.00009-5","volume":"146","author":"Z Illes","year":"2017","unstructured":"Illes Z, Blaabjerg M. Cerebrospinal fluid findings in Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathies. Handb Clin Neurol 2017; 146:125\u201338.","journal-title":"Handb Clin Neurol"},{"issue":"Suppl1","key":"436_CR11","doi-asserted-by":"publisher","first-page":"i2","DOI":"10.1136\/jnnp.2004.061655","volume":"76","author":"J Stone","year":"2005","unstructured":"Stone J, Carson A, Sharpe M. Functional symptoms and signs in neurology: assessment and diagnosis. J. Neurol Neurosurg Psychiatry 2005; 76(Suppl 1):i2\u201312.","journal-title":"J. Neurol Neurosurg Psychiatry"},{"key":"436_CR12","doi-asserted-by":"crossref","first-page":"564098","DOI":"10.1155\/2015\/564098","volume":"2015","author":"Y Wang","year":"2015","unstructured":"Wang Y, Sun S, Zhu J, Cui L, Zhang HL. Biomarkers of Guillain-Barre syndrome: some recent progress, more still to be explored. Mediators Inflamm 2015; 2015:564098.","journal-title":"Mediators Inflamm"},{"key":"436_CR13","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.cyto.2010.05.005","volume":"51","author":"PP Sainaghi","year":"2010","unstructured":"Sainaghi PP, Collimedaglia L, Alciato F, et al. The expression pattern of inflammatory mediators in cerebrospinal fluid differentiates Guillain-Barre syndrome from chronic inflammatory demyelinating polyneuropathy. Cytokine 2010; 51:138\u201343.","journal-title":"Cytokine"},{"key":"436_CR14","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.neurol.2014.10.009","volume":"170","author":"J Svahn","year":"2014","unstructured":"Svahn J, Antoine JC, Camdessanche JP. Pathophysiology and biomarkers in chronic inflammatory demyelinating polyradiculoneuropathies. Rev Neurol (Paris) 2014; 170:808\u201317.","journal-title":"Rev Neurol (Paris)"},{"key":"436_CR15","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.immuni.2014.02.002","volume":"40","author":"AM Curtis","year":"2014","unstructured":"Curtis AM, Bellet MM, Sassone-Corsi P, O\u2019Neill LA. Circadian clock proteins and immunity. Immunity 2014; 40:178\u201386.","journal-title":"Immunity"},{"key":"436_CR16","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.bbi.2016.04.016","volume":"57","author":"K Ella","year":"2016","unstructured":"Ella K, Csepanyi-Komi R, Kaldi K. Circadian regulation of human peripheral neutrophils. Brain Behav Immun 2016; 57:209\u201321.","journal-title":"Brain Behav Immun"},{"key":"436_CR17","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/j.1085-9489.2005.0010203.x","volume":"10","author":"PA van Doom","year":"2005","unstructured":"van Doom PA. Treatment of Guillain-Barre syndrome and CIDP. J Peripher Nerv Syst 2005; 10:113\u201327.","journal-title":"J Peripher Nerv Syst"},{"key":"436_CR18","first-page":"Cd001446","volume":"10","author":"RA Hughes","year":"2016","unstructured":"Hughes RA, Brassington R, Gunn AA, van Doom PA. Corticosteroids for Guillain-Barre syndrome. Cochrane Database Syst Rev 2016; 10:Cd001446.","journal-title":"Cochrane Database Syst Rev"}],"container-title":["European Cytokine Network"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1684\/ecn.2019.0436.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1684\/ecn.2019.0436\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1684\/ecn.2019.0436.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.jle.com\/10.1684\/ecn.2019.0436","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:27:32Z","timestamp":1790674052000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.techscience.com\/ECN\/v30n4\/65383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["436"],"URL":"https:\/\/doi.org\/10.1684\/ecn.2019.0436","relation":{},"ISSN":["1952-4005"],"issn-type":[{"value":"1952-4005","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"11 November 2019","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 M\u00e4rz 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}